Clinical Trial

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-25.
Trial Details
NCT Number NCT07051629
Lead Sponsor Suninflam Inc
Conditions Epilepsy, Healthy Volunteer
Enrollment 88 participants
Start Date 2025-06-16
Primary Completion 2027-01-15 (estimated)
Study Completion 2027-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-15